Cigna Group stock (US1255231003): shares steady as company plans to end GLP-1 weight-loss coverage for employees

Cigna Group shares on the NYSE traded around USD 272 on Wednesday as the U.S. health services group confirmed plans to stop covering GLP-1 weight-loss drugs for its own employee health plan from July 2026, while its broader customer coverage for diabetes therapies remains unchanged.

Cigna Group stock traded around the USD 272 mark on the New York Stock Exchange on Wednesday as investors digested news that the U.S. health services provider will end coverage of GLP-1 weight-loss drugs for its own employee health plan from July 2026, while keeping coverage for diabetes treatments in place for other plans, according to company communications cited by GuruFocus on 06/03/2026 and reporting from the United States.

According to a report on 06/03/2026, Cigna said that beginning 07/01/2026 it will discontinue coverage of GLP-1 weight-loss medications, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, for roughly 67,700 employees in its U.S. health plan, although members already using these drugs can refill prescriptions through 06/30/2026, and this adjustment will not affect other Cigna-administered health plans or coverage of GLP-1 drugs prescribed for type 2 diabetes.

The stock recently showed a last close at about USD 272.72 and opened around USD 272.37 on Wednesday, with a 52-week range between approximately USD 239.51 and USD 338.89, according to price data for NYSE: CI as of early June 2026.

The company remains a significant component of the U.S. health care space, and trading in its primary listing on the NYSE under ticker CI provides the main price reference for investors, while some secondary trading also occurs on European venues, such as Tradegate in Germany, where quotes are typically provided in euros for local investors following the U.S.-listed equity.

As of: 06/03/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Cigna Group
• Sector/industry: Health services and managed care
• Headquarters/country: Bloomfield, United States
• Core markets: United States with selected international health services
• Key revenue drivers: Pharmacy benefit and health services through Evernorth, commercial and government medical plans in Cigna Healthcare
• Home exchange/listing venue: New York Stock Exchange (CI)
• Trading currency: USD

Cigna Group: core business model

Cigna Group operates as a diversified health services company that combines medical insurance, pharmacy benefit management, and related care solutions, with revenue primarily generated by Evernorth Health Services and Cigna Healthcare programs for employers, government entities, and individuals.

Cigna Group in peer comparison

Within the U.S. managed care and health services universe, Cigna Group is often viewed alongside peers such as UnitedHealth Group, Elevance Health, and CVS Health, all of which combine insurance activities with various care delivery and pharmacy or benefit management capabilities in the United States.

For instance, Cigna reported a trailing price-to-earnings ratio around 9.1 as referenced by GuruFocus on 06/03/2026, which can be compared with higher multiples often seen at larger diversified peers such as UnitedHealth Group, while Cigna's 52-week trading range from about USD 239.51 to USD 338.89 shows that its current level near USD 272 is below both that recent high and some consensus price targets in the sector as compiled by certain analyst aggregators.

Conclusion

Cigna Group's decision to stop covering GLP-1 weight-loss drugs for its U.S. employee health plan from 07/01/2026 highlights the cost and utilization pressures around newer obesity medications while preserving coverage for type 2 diabetes therapies in other plans.

In the equity market, the stock's current level near USD 272 and a trailing price-to-earnings ratio around 9.1 leave it trading below its 52-week high and some peer valuations, while sector comparisons within the broader U.S. managed care and health services group provide investors with additional context for assessing the company's positioning.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.